Cited by 177Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major DepressionMaternal Mental Health During Pregnancy and Postpartum

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder: Twenty-four-week placebo-controlled dose-ranging study

Open access

Allgulander, Christer, Hackett, David, Salinas, Eliseo·2001·British Journal of Psychiatry

DOI 10.1192/bjp.179.1.15

Open this paper in CoChat — free account Open PDF

Abstract

Background: Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. Aims: To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. Method: A total of 541 out-patients, 18–86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER. Results: All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups. Conclusions: Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1192/bjp.179.1.15

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Untitled work
(1976) · Medical Entomology and Zoology · Cited by 8,899
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Antidepressants for the Treatment of Generalized Anxiety Disorder
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 416
Buspirone
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 333
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 2

1989, ‘COSTART’: Coding Symbols for Thesaurus of Adverse Reactions Terms
Kessler R. C. & Wittchen H. -U. (2001) GAD-associated impairment controlling for MDE in the NCS and MIDUS surveys. Psychological Medicine, in press

Sorted by citations

Items 101–177 of 177

Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature
Nguyen, C. T., MacEntee, M. I., Mintzes, B. J., & Perry, T. L. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0141-5 · Cited by 17
Drug Class Review: Second-Generation Antidepressants
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Cited by 17
Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding study
Naukkarinen, H., Raassina, R., Penttinen, J., Ahokas, A., Jokinen, R., Koponen, H., Lepola, U. M., Kanerva, H., Lehtonen, L., Pohjalainen, T., et al. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.03.002 · Cited by 17
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder
Mavranezouli, I., Meader, N., Cape, J. D., & Kendall, T. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0031-z · Cited by 16
Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release
Boyer, P., Mahé, V., & Hackett, D. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.05.010 · Cited by 15
Self-citation
Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients
Thase, M. E., Ninan, P. T., Musgnung, J. J., & Trivedi, M. H. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.10m00979blu · Cited by 15
Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom
Guest, J. F., Russ, J., & Lenox‐Smith, A. (2005) · The European Journal of Health Economics · doi:10.1007/s10198-004-0272-z · Cited by 14
Le traitement pharmacologique de l’anxiété généralisée : utilisation rationnelle et limitations
Boulenger, J.-P., & Capdevielle, D. (2007) · L Encéphale · doi:10.1016/s0013-7006(07)91562-6 · Cited by 14
The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?
Masand, P. S., & Gupta, S. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.5.485 · Cited by 14
Treatment of generalized anxiety disorder
Durham, R. C. (2004) · Psychiatry · doi:10.1383/psyt.3.4.30.32903 · Cited by 13
History Repeats Itself: Pharmacodynamic Trends in the Treatment of Anxiety Disorders
Schwartz, T. L., Nihalani, N. D., Simionescu, M., & Hopkins, G. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382214 · Cited by 13
Determination of Serotonin-Norepinephrine Reuptake Inhibitor Antidepressants in Pharmaceuticals and Biological Material
Saka, C., & Şahi̇n, Ö. (2013) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2011.645377 · Cited by 12
Paroxetine in the treatment of generalised anxiety disorder
Snyderman, S. H., Rynn, M. A., Bellew, K. M., & Rickels, K. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.8.1799 · Cited by 12
The current status of the diagnostic validity and treatment of generalized anxiety disorder
Hunt, C. J. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200203000-00006 · Cited by 12
ECNP Consensus Meeting March 2000
Montgomery, D. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00147-x · Cited by 13
Treatment of generalized anxiety disorder
Durham, R. C. (2007) · Psychiatry · doi:10.1016/j.mppsy.2007.03.003 · Cited by 12
The best next drug in the course of generalized anxiety disorders: the “PN-GAD-algorithm”
Linden, M., Bandelow, B., Boerner, R. J., Brasser, M., Kasper, S. F., Möller, H., Pyrkosch, L., Volz, H., & Wïttchen, H. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.722645 · Cited by 11
Depression in primary care: effectiveness of venlafaxine extended-release in elderly patients
Cervera‐Enguix, S., Baca‐Baldomero, E., García-Calvo, C., & Prieto, R. (2004) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2003.11.001 · Cited by 11
Antidepressants for generalised anxiety disorder (GAD)
Kapczinski, F. P., Souza, J. J. D. S., da Cunha, A. A. B. M., & Schmitt, R. R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003592.pub2 · Cited by 11
Retracted
Estimation of symptom-free days in generalized anxiety disorder
Wan, G. J., Zhang, H. F., Tedeschi, M., & Hackett, D. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x96245 · Cited by 11
Self-citation
Investigating the effects and efficacy of self-compassion intervention on generalized anxiety disorders
Luo, X., Shen, Y., Sun, L., Qi, X., Hong, J., Wang, Y., Che, X., & Lei, Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.117 · Cited by 10
Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder
Pae, C., Lim, H. K., Ajwani, N., Lee, C., & Patkar, A. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.603 · Cited by 10
Efficacy of Pregabalin and Venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebo-controlled 8-week trial
Murphy, T. K., Nivoli, G., Petralia, A., & Mandel, F. S. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.01.370 · Cited by 10
Therapeutic options: Addressing the current dilemma
Dinan, T. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.04.004 · Cited by 11
Generalized Anxiety Disorder: Raising the Expectations of Treatment
Allgulander, C., Sheehan, D. V., Sheehan, A. D. V., MD, & MBA (2015) · Psychopharmacology Bulletin · doi:10.64719/pb.6856 · Cited by 9
Self-citation
Venlafaxine: a new class of antidepressant
Hardy, J., Argyropoulos, S. V., & Nutt, D. (2002) · Hospital Medicine · doi:10.12968/hosp.2002.63.9.1952 · Cited by 8
The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?
Baldwin, D. S., & Tiwari, N. (2009) · CNS Spectrums · doi:10.1017/s1092852900027243 · Cited by 8
Angststörungen
Domschke, K., Kapfhammer, H., & Deckert, J. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_69 · Cited by 9
Venlafaxine Withdrawal Syndrome
Baboolal, N. S. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117427.05703.f2 · Cited by 8
Evidence-based pharmacotherapy of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.008 · Cited by 8
Self-citation
Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder
Baldwin, D. S., Buis, C., & Mayers, A. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.5.717 · Cited by 7
Anxiety levels and related pharmacological drug treatment: a memorandum for the third millennium.
Pasquini, M., & Berardelli, I. (2009) · PubMed · Cited by 7
Chapter 50. Treatment of Anxiety Disorders
Choi, S., & Stein, M. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as50 · Cited by 7
Conflict of interest and the British Journal of Psychiatry
Wright, I. C. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.1.82 · Cited by 7
A randomized, double‐blinded, placebo‐controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorder
Otsubo, T., Watanabe, K., Inoue, T., Inagaki, A., Kikuchi, T., Nomoto, K., Higa, S., Asami, Y., Sun, B., & Marschall, K. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13907 · Cited by 5
Long-term outcome of anxiety disorders: a review of double-blind studies
THUILE, J., EVEN, C., & Rouillon, F. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831a726d · Cited by 5
Two formulations of venlafaxine are bioequivalent when administered as open capsule mixed with applesauce to healthy subjects
Jain, R., Srivastava, A., & Panda, J. (2011) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.98989 · Cited by 5
Depression and anxiety
(2005) · CRC Press eBooks · doi:10.1201/b14455-5 · Cited by 5
Pharmacotherapy for Generalized Anxiety Disorder
Katzman, M. A., Copeland, A., Klassen, L. J., Chokka, P. R., & Brawman‐Mintzer, O. (2011) · Psychiatric Annals · doi:10.3928/00485713-20110203-08 · Cited by 4
The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder
Rickels, K., Gallop, R., & Cleary, S. D. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001027 · Cited by 3
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 4
Pharmakotherapie bei Angsterkrankungen
Plag, J., Siegmund, A., & Ströhle, A. (2009) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747.57.3.185 · Cited by 3
WCA Recommendations for the Long-Term Treatment of Anxiety Disorders
Zohar, J. (2003) · CNS Spectrums · doi:10.1017/s1092852900006891 · Cited by 3
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_414 · Cited by 2
An open‐label, long‐term extension, multicenter study to evaluate the safety and efficacy of venlafaxine extended release in Japanese outpatients with generalized anxiety disorder
OTSUBO, T., Watanabe, K., Inoue, T., Inagaki, A., Kikuchi, T., Nomoto, K., Higa, S., Asami, Y., Sun, B., & Marschall, K. (2026) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70371 · Cited by 2
Angststörungen
Domschke, K., Kapfhammer, H., & Deckert, J. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_69-1 · Cited by 3
The jumping to conclusions bias associated with symptoms in schizophrenia: which factors influence this bias?
Korkmaz, Ş. A., & Can, S. S. (2020) · Journal of Cognitive Psychology · doi:10.1080/20445911.2020.1764570 · Cited by 2
Pharmacotherapy of Anxiety
Nash, J. R., & Nutt, D. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn024 · Cited by 2
A Pilot Study of Antidepressant Therapy on Sleep Architecture in Patients with Depression in Congo
Dhillon, H., & Sasidharan, S. (2021) · Taiwanese Journal of Psychiatry · doi:10.4103/tpsy.tpsy_17_21 · Cited by 1
Safety of lactational exposure to venlafaxine on the rat mammary gland development and carcinogenesis in F1 female offspring
Altieri, M. A., da Silva, A. S., Moreira, S. D. S., Zapaterini, J. R., Arena, A. C., & Barbisan, L. F. (2023) · Reproductive Toxicology · doi:10.1016/j.reprotox.2023.108451 · Cited by 1
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-319-56015-1_414-1 · Cited by 1
Reporting of randomised trials
Jainer, A. K., & Acharya, S. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.2.185 · Cited by 1
Trastornos por ansiedad y comórbidos del consumo de psicotrópicos y otras sustancias de abuso
y Machorro, M. S. (2008) · Cited by 1
Pharmacological Treatment of Generalized Anxiety Disorder (GAD)
Baldwin, D. S. (2020) · Wiley eBooks · doi:10.1002/9781119189909.ch14 · Cited by 1
Venlafaxina retard y trastorno por dependencia de alcohol
Anillo, D. C., Yuste, A. R., Velarde, C. M., & Gisbert, M. V. C. (2007) · Adicciones · doi:10.20882/adicciones.311
Recommendations for the Long-Term Treatment of Anxiety Disorders
Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Okasha, A., Zohar, J., Allgulander, C., Cassano, G. B., Pollack, M. S., & Ameringen, M. V. (2003)
Self-citation
VENLAFAXINE INDUCED DELIRIUM IN A WITHDRAWAL SYNDROME
Ifteni, P. I., Teodorescu, A., Taran, L. M., & Burtea, V. (2013) · Bulletin of the Transilvania University of Brasov Series VI Medical Sciences
Was hilft, wenn Sorgen außer Kontrolle geraten?
Volz, H., & Stieglitz, R. (2012) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-012-0048-8
Generalized Anxiety Disorder in Adults
Barabie, S. M., Aljohani, R. R., Felemban, A. F., Alharbi, A. M., Alqadheb, A., Alshammari, R. D. A., Aljerayed, M. K., Al-Qahtani, A. A., Natto, L. H., Alrefaidy, F. H., et al. (2019) · EC Microbiology
Un método para controlar una tasa alta de respuesta al placebo en una comparación de venlafaxina XR y diacepam en el tratamiento a corto plazo de pacientes con trastorno de ansiedad generalizada
Hackett, D., Haudiquet, V., & Salinas, E. O. (2003) · European psychiatry (Ed Española) · doi:10.1017/s1134066500007748
Self-citation
Terapia a largo plazo del trastorno de ansiedad generalizada
Rouillon, F. (2004) · European psychiatry (Ed Española) · doi:10.1017/s1134066500004483
Adaptación social y trastorno de ansiedad generalizada: un estudio a largo plazo controlado con placebo de la venlafaxina de liberación prolongada
Boyer, P., Mahé, V., & Hackett, D. (2004) · European psychiatry (Ed Española) · doi:10.1017/s1134066500008468
Self-citation
Facteurs de variabilité de l'effet de substances anxiolytiques sur le labyrinthe en croix surélevé chez la Souris
Clénet, F. (2005) · OpenGrey (Institut de l'Information Scientifique et Technique)
The Plot-poll Redesigned: Lessons from the Deployment of a Collective Mood-tracker in an Online Support Group
Ivanov, A., & Mileva, E. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-10831-5_5
Angststörungen
Rupprecht, R., & Möller, H. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_43
Angststörungen
Kapfhammer, H. (2008) · Springer eBooks · doi:10.1007/978-3-540-33129-2_58
Angststörungen
Kapfhammer, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_57
New Research
(2002) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.7.2.10.22509
Treatment of generalised anxiety and somatoform disorders
Tyrer, P. J., & Baldwin, D. S. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.033
Editor's response
Wilkinson, G. (2002) · The British Journal of Psychiatry · doi:10.1192/s0007125000160532
A Prospective Treatment for Selective Mutism through an Analysis of Social Anxiety Disorder
Patel, R., & Kirk, L. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3236
Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_133
Antidepressiva
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00002-7
Angst- oder furchtbezogene Störungen
Domschke, K., & Zwanzger, P. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_69-2
Pharmaceutical pollutant reshapes behavioural variation in the eastern mosquitofish, Gambusia holbrooki
Rafeeq, R., Aich, U., Saaristo, M., & Wong, B. B. M. (2026) · Animal Behaviour · doi:10.1016/j.anbehav.2026.123718
BindingDB Entry 50018698: Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER.
BindingDB (2009) · UC San Diego · doi:10.7270/q2ws8sx8

Authors: Allgulander, C., Hackett, D., & Salinas, E.
Corresponding author: Allgulander, Christer
Venue: British Journal of Psychiatry
Publisher: Royal College of Psychiatrists
Published: 2001-07
Volume: 179
Issue: 1
Pages: 15-22
ISSN: 0007-1250 (ISSN-L)
1472-1465
DOI: 10.1192/bjp.179.1.15
OpenAlex: W2122087038
Cited by: 175
References: 23
Citations by year: 2026: 3 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 7 · 2012: 5
FWCI: 25.99
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.cambridge.org/core/terms (unspecified, 6029 d)
Locations: The British Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Karolinska Institutet
Topics: Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords: venlafaxine extended release, generalized anxiety disorder, antidepressant efficacy, drug safety, long-term treatment, dose comparison, treatment discontinuation
MeSH terms: Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Aged, 80 and over, Anxiety Disorders, Chronic Disease, Cyclohexanols, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder: Twenty-four-week placebo-controlled dose-ranging study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks